Estrogen- and antiestrogen-responsiveness of HEC1A endometrial adenocarcinoma cells in culture. (Q48001017)

7 February 2018

title

Estrogen- and antiestrogen-responsiveness of HEC1A endometrial adenocarcinoma cells in culture. (English)

1 reference

7 February 2018

endometrial adenocarcinoma

main subject

1 reference

E Castro-Rivera

1

1 reference

7 February 2018

S Safe

series ordinal

2

1 reference

7 February 2018

publication date

1 March 1998

1 reference

7 February 2018

number of pages

9

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

inferred from page(s)

published in

1 reference

7 February 2018

volume

64

1 reference

7 February 2018

issue

5-6

1 reference

7 February 2018

page(s)

287-295

1 reference

7 February 2018

The epidemiology of endometrial cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Of historical interest. General Grant fights cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Body mass index, weight gain, and risk of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Association of Exogenous Estrogen and Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Reproductive factors and risk of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Risk of endometrial cancer after tamoxifen treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Second cancers after adjuvant tamoxifen therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Should clinicians be concerned about the carcinogenic potential of tamoxifen?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Tamoxifen and the induction of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Tamoxifen and tumorigenicity: a predictable concern

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Establishment of a cell line of human endometrial adenocarcinoma in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa)

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Insensitivity of cathepsin D gene to estradiol in endometrial cells is determined by the sequence of its estrogen responsive element.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Processing and estrogen regulation of the 52-kilodalton protein inside MCF7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Development of gel staining techniques for detecting the secretion of procathepsin D (52-kDa protein) in MCF-7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Inhibition of estrogen-induced activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the MCF-7 human breast cancer and other cell lines transfected with vitellogenin A2 gene promoter constructs

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Identification of cis-acting regulatory elements in the promoter region of the rat brain creatine kinase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

The stimulation of uterine complement component C3 gene expression by antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Estrogen activates migration potential of endometrial cancer cells through basement membrane.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Determination of hormonal response in uterine cancer cell lines by the ATP bioluminescence assay and flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells, and yeast-based estrogen receptor assays: no apparent synergism

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Cloning of a novel receptor expressed in rat prostate and ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2897%2900202-1

7 January 2021

10.1016/S0960-0760(97)00202-1

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

9618030

1 reference

7 February 2018